ArticleScientific reports2019
Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 145 citations in OpenAlex.
- Review
- Phage as a prospective arsenal against superbugs.Molecular biology reports · 2026Review
- Cystic fibrosis: insights from zebrafish models.Disease models & mechanisms · 2026Review
- Phage Therapy as an Alternative Strategy Against Pseudomonas aeruginosa: A Narrative Review of Preclinical and Clinical Evidence.MicrobiologyOpen · 2026Review
- Decolonizing the gut from multidrug-resistant bacteria: Current strategies and future perspectives.World journal of methodology · 2026Review
- Steering the course: targeting and exploiting surface receptors in phage therapy.Journal of bacteriology · 2026Review
- Bacteriophage Therapy in Cystic Fibrosis: Emerging Strategies for Managing ChronicDrug design, development and therapy · 2026Review
- Latest Advances in Inhalable Dry Powder Bacteriophage Therapy for Pulmonary Infections.Pharmaceutics · 2025Review
- Evaluating Bacteriophage Impact on Vibrio Composition in the Gut of Broad-Nosed Pipefish (Syngnathus typhle).Environmental microbiology reports · 2025Article
- Marine Bacteriophages as Next-Generation Therapeutics: Insights into Antimicrobial Potential and Application.Viruses · 2025Review
- Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside.MedComm · 2025Review
- Article
- Intracellular Pseudomonas aeruginosa persist and evade antibiotic treatment in a wound infection model.PLoS pathogens · 2025Article
- Review
- Mapping the oxidative landscape in cystic fibrosis: methodological frontiers and application.Frontiers in pharmacology · 2025Review
- A New Insight into Phage Combination Therapeutic Approaches Against Drug-Resistant Mixed Bacterial Infections.PHAGE (New Rochelle, N.Y.) · 2024Review
- Zebrafish (International journal of molecular sciences · 2024Review
- Zebrafish as an effective model for evaluating phage therapy in bacterial infections: a promising strategy against human pathogens.Antimicrobial agents and chemotherapy · 2024Review
- Integrative structural analysis of Pseudomonas phage DEV reveals a genome ejection motor.Nature communications · 2024Article
- Navigating ESKAPE Pathogens: Considerations and Caveats for Animal Infection Models Development.ACS infectious diseases · 2024Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic fibrosis (CF) is a hereditary disease due to mutations in the CFTR gene and causes mortality in humans mainly due to respiratory infections caused by Pseudomonas aeruginosa. In a previous work we used phage therapy, which is a treatment with a mix of phages, to actively counteract acute P. aeruginosa infections in mice and Galleria mellonella larvae. In this work we apply phage therapy to the treatment of P. aeruginosa PAO1 infections in a CF zebrafish model. The structure of the CFTR channel is evolutionary conserved between fish and mammals and cftr-loss-of-function zebrafish embryos show a phenotype that recapitulates the human disease, in particular with destruction of the pancreas. We show that phage therapy is able to decrease lethality, bacterial burden, and the pro-inflammatory response caused by PAO1 infection. In addition, phage administration relieves the constitutive inflammatory state of CF embryos. To our knowledge, this is the first time that phage therapy is used to cure P. aeruginosa infections in a CF animal model. We also find that the curative effect against PAO1 infections is improved by combining phages and antibiotic treatments, opening a useful therapeutic approach that could reduce antibiotic doses and time of administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.